Mirum Pharmaceuticals Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect the Board’s three Class I nominees for director to hold office until the Company’s 2029 annual meeting of stockholders and their successors, or until earlier death, resignation or removal.

2. 2

   Ratification of Selection of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the Audit Committee’s selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

3. 3

   Advisory Vote on Executive Compensation (Say on Pay

   ManagementBoard: FOR

   Approve, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement, including the Compensation Discussion and Analysis, compensation tables and narrative discussion.

   More detail

   This advisory (non-binding) proposal asks stockholders to approve the Company’s disclosed executive compensation program as a whole, effectively endorsing the Board’s approach to pay design. Management seeks this approval as an affirmation that its mix of base salary, performance-based cash bonuses and long‑term equity incentives (stock options, RSUs and PSUs) appropriately aligns executive incentives with company performance and stockholder value. The Company’s program places substantial pay “at risk” — a high percentage of CEO and NEO compensation is tied to performance metrics and equity appreciation, with PSU vesting linked to net product sales targets and time-based vesting for RSUs and options. Notably, the Company reported strong 2025 operating results, including $521.3 million in net product sales and multiple regulatory approvals and pipeline progress, which materially informed bonus and PSU outcomes for the year. The Board highlights that an independent compensation consultant and a peer group review informed grant levels and design; the Board also points to a prior say-on-pay result (approximately 96% support in 2025) as validation of its approach. While the vote is non-binding, a strong shareholder endorsement would support continuation of the current compensation framework; a significant negative vote could prompt the Compensation Committee to revise program design, performance metrics, or disclosure. Investors may weigh potential governance considerations — including the overall magnitude of realized compensation, severance/change-in-control protections, and a CEO-to-median pay ratio of 24:1 — when deciding how to vote. The Board recommends a “For” vote on the basis that the program incentivizes long‑term value creation, aligns management and shareholder interests, and is consistent with market practices, while committing to consider stockholder feedback in future compensation decisions.

Upcoming shareholder meetings at Mirum Pharmaceuticals Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Mirum Pharmaceuticals Inc 2026 annual meeting?

Mirum Pharmaceuticals Inc (MIRM) holds its 2026 annual shareholder meeting on Monday, June 15, 2026.

What is the record date for the Mirum Pharmaceuticals Inc 2026 meeting?

The record date for the Mirum Pharmaceuticals Inc 2026 meeting is Monday, April 20, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Mirum Pharmaceuticals Inc's 2026 meeting?

The board is presenting 3 director nominees at the Mirum Pharmaceuticals Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Mirum Pharmaceuticals Inc 2026 meeting?

Shareholders will vote on 3 proposals at the Mirum Pharmaceuticals Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.